Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Closer Monitoring Recommended for Older Patients Treated With Dolutegravir for HIV

The maximum concentration of the integrase inhibitor dolutegravir (DTG) was significantly higher in people living with HIV who are more than 60 years old compared with younger individuals, according to new findings published in Clinical Infectious Diseases.There have been recent concerns about DTG-related neuropsychiatric toxicity, especially among older patients with HIV.

Published
11 June 2018
From
Infectious Disease Advisor
FDA says Prezcobix should not be given to pregnant women

Darunavir/cobicistat — marketed as Prezcobix (Janssen) in the United States — should not be given to pregnant women with HIV because of substantially lower exposures of the two medications during pregnancy, the FDA said. The agency updated the label for the once-daily, fixed-dose tablet to reflect the change, which it said was based on data from a small clinical trial involving pregnant women.

Published
11 June 2018
From
Healio (requires free registration)
Potential interactions between ART and other medications present in over half of older HIV-positive people

Over half of older HIV-positive people are at risk of experiencing an interaction between their anti-HIV drugs and medications taken for the treatment of non-HIV-related

Published
31 May 2018
By
Michael Carter
Differing drug distribution in penis and rectum of men taking TDF/FTC PrEP

Men using tenofovir/emtricitabine (TDF/FTC) for preexposure prophylaxis (PrEP) had detectable drug levels in the urethra more often than on the glans penis, according to results of an 18-man study. FTC concentrations proved similar on urethral and rectal swabs, but tenofovir (TFV) levels were lower on urethral specimens than on rectal swabs.

Published
25 May 2018
From
NATAP
How Well Do Docs Manage Potential Conflicts Between Hep C and HIV Meds?

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Published
10 April 2018
From
Poz
TAF only superior to TDF when used with a boosting agent

The benefits of tenofovir alafenamide (TAF) over tenofovir disoproxil fumarate (TDF) may have been overstated, according to the results of a meta-analysis published in the

Published
10 April 2018
By
Michael Carter
Twice-daily dolutegravir is safe and effective when used alongside TB treatment

Twice-daily dosing of dolutegravir when combined with the tuberculosis (TB) drug rifampicin is safe and effective and will allow dolutegravir to be used alongside TB treatment as

Published
07 March 2018
By
Keith Alcorn
Dolutegravir and Rifapentine study stopped due to serious toxicities

A study examining pharmacokinetic interactions between the first-line HIV drug dolutegravir and a once-weekly tuberculosis regimen was terminated early after NIH researchers found that the combined use of the treatments led to “unexpected and serious toxicities” in healthy participants.

Published
01 March 2018
From
Medical Brief
Taking multiple Rx drugs raises risks for aging adults with and without HIV

Taking five or more prescription medications increases the risk of hospitalization and death in older adults infected with HIV and comparable adults without HIV. The findings of this Yale-led study highlight the potential risks of prescribing additional drugs to patients with multiple medical conditions.

Published
01 February 2018
From
Yale News
New 'mini-pillbox' device could deliver three HIV drugs in a single once-weekly dose

A new oral device that is taken once a week in a capsule could deliver two or three antiretroviral drugs and significantly reduce the risk

Published
09 January 2018
By
Keith Alcorn
← First12345...22Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.